Ophthalmic Drug Delivery Systems

Most ophthalmic drugs are weak bases formulated at acidic pH to enhance stability. However, this increases their ionization, which reduces their ability to penetrate the corneal membrane. Additionally, rapid tear drainage and diffusion-limited absorption across the cornea further decrease drug concentration at the absorption site, limiting therapeutic effectiveness.

Viscous formulations like ointments and suspensions prolong corneal contact time, allowing drugs more opportunity to penetrate the corneal membrane. By increasing the duration of drug exposure to the eye, these formulations enhance absorption compared to standard solutions. However, they lack precise control over drug release rates.

Drugs with short half-lives require frequent administration to maintain therapeutic levels. This increases the risk of local irritation and systemic side effects from repeated dosing. Frequent applications also reduce patient compliance and increase the burden of treatment, making consistent therapy difficult to achieve.

Ocular inserts, or ocuserts, contain a drug reservoir core surrounded by ethylene-vinyl acetate membranes that regulate release rates. Inserted in the lower fornix conjunctiva, they deliver drugs like pilocarpine at constant rates of 20 or 40 micrograms per hour for up to seven days. This controlled approach replaces multiple daily eye drops and maintains consistent therapeutic levels.

Physicochemical properties, including ionization state and molecular structure, directly influence a drug's ability to cross the corneal membrane through diffusion. Weak bases like pilocarpine and atropine are formulated at acidic pH for stability, but this increases ionization and reduces corneal penetration. These properties fundamentally determine absorption efficiency and therapeutic outcomes.

Ocuserts deliver pilocarpine at zero-order kinetics, maintaining constant drug levels for up to seven days compared to conventional drops requiring multiple daily applications. This continuous delivery minimizes fluctuations in drug concentration, reduces local irritation and systemic exposure, and improves patient compliance by eliminating frequent dosing requirements.

Tear drainage rapidly removes drugs from the eye, reducing drug concentration at the corneal absorption site and limiting the time available for diffusion across the corneal membrane. This physiological barrier significantly reduces bioavailability of topical ophthalmic drugs, necessitating strategies like viscous formulations or controlled-release systems to enhance therapeutic effectiveness.